Friday, 14 Feb 2020

You are here

PEXIVAS - Plasma Exhange Fails to Boost Outcomes in Severe AAV

Patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis may have severe or life-threatening disease. It is unknown if ther addition of aggressve plasma exchange therapy can signficantly improve outocomes.

The PEXIVAS randomized control trial addressed this question and showed that plasma exchange did not reduce the incidence of death or ESKD. A reduced-dose regimen of glucocorticoids was noninferior to a standard-dose regimen with respect to death or end-stage kidney disease (ESKD). 

This trial evaluated 352 patients with severe ANCA-associated vasculitis (defined as a GFR <50 cc or diffuse pulmonary hemorrhage). Patients were given 2 different regimens of glucocorticoids and then randomlized to seven plasma exchanges for 14 days or no plasma exchange.  Patients were followed for up to 7 years for the primary composite outcome of death from any cause or ESKD.

Death or ESKD occurred in 28% in the plasma-exchange group and in 31% in the control group (hazard ratio, 0.86; 95% confidence interval [CI], 0.65 to 1.13; P=0.27).

Death from any cause or ESKD occurred in 28% in the reduced-dose steroid group and in 25.5% of the standard-dose steroid group, which met the criterion for noninferiority.

Serious infections at 1 year were less common in the reduced-dose group than in the standard-dose group (incidence rate ratio, 0.69; 95% CI, 0.52 to 0.93), but other secondary outcomes were similar in the two groups.

In those with severe ANCA-associated vasculitis, the use of plasma exchange did not alter the outcomes of death or ESKD.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Shingles Vaccine Lowers Risk of CVA

Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.

EULAR Recommendations on Sjögren’s Syndrome

The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.